Unita di Ricerca Clinica

Group Leader:
Prof. Carlo Gambacorti-Passerini

Group Members:
Rocco Piazza
Sara Redaelli
Vera Magistroni
Monica Ceccon
Carla Donadoni
Alessandra Pirola
Michela Viltadi
Praveen Khandelwal
Nitesh Sharma
Silvia Mori
Nicoletta Cordani
Cristian Rizzo

Contact:
Via Pergolesi 33, 20900 Monza, Italy
+39 0392339553
carlo.gambacorti@unimib.it

Afiliation:
Dept. of Health Sciences
University of Milano-Bicocca

Funding:
Italian Association for Cancer Research
Regione Lombardia

Description:
- Identification of molecular pathogenesis of hematological cancers using genome sequencing
- Molecular mechanisms governing transition from chronic phase to blast crisis in CML
- Target validation of oncogenic fusion genes in Prostatic Carcinoma
- ABL-inhibitors against ABL315 mutant form and other imatinib-resistance mechanisms
- Structural characterization and screening of small-molecule inhibitors of the Anaplastic Lymphoma Kinase
- Use of new tyrosine kinase inhibitors to overcome imatinib resistance in patients
- ILTE - Imatinib Long Term side-Effects study
- ISAV STUDY - Imatinib Suspension and Validation

Collaborators: Prof. Chiarle Research group

Publications:
1: Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L, Piazza R. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive
lymphoma patients. J Natl Cancer Inst. 2014 Feb 1;106(2).

2: Piazza R, Magistroni V, Pirola A, Redaelli S, Spinelli R, Redaelli S, Galbiati M, Valletta S, Giudici G, Cazzaniga G, Gambacorti-Passerini C. CEQer: a graphical tool for copy number and allelic imbalance detection from whole-exome sequencing data. PLoS One. 2013 Oct 4;8(10):e74825.

3: Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013 Jan;45(1):18-24.

4: Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C.
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-32.

5: Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi
M, Flynn D, Gambacorti-Passerini C. Three novel patient-derived BCR/ABL mutants
show different sensitivity to second and third generation tyrosine kinase
inhibitors. Am J Hematol. 2012 Nov;87(11):E125-8.

Tools:
ALK+ tumors grown in mouse models

Techniques:
High Throughput Screening